1. Elimination of l-Asparaginase in Children Treated for Acute Lymphoblastic Leukemia
- Author
-
V. Wahn, H. Juergens, D. Koerholz, W. Nuernberger, M. Brueck, and U. Goebel
- Subjects
Radial immunodiffusion ,Chemotherapy ,Asparaginase ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Induction chemotherapy ,Urine ,Pharmacology ,medicine.disease ,chemistry.chemical_compound ,chemistry ,Pharmacokinetics ,Western blot ,Acute lymphocytic leukemia ,Immunology ,medicine ,Pharmacology (medical) ,General Pharmacology, Toxicology and Pharmaceutics ,business - Abstract
The elimination of l-asparaginase (l-Asp) was studied in 8 children treated for acute lymphoblastic leukemia according to the CoALL 82 protocol. The patients received four doses of l-Asp as a single agent during induction chemotherapy. We studied the elimination of l-Asp during the first infusion in 1 child, during the second in 3, during the third in 2 and during the forth in 2 children. Using Western blot technique and an experimental rabbit antibody to l-Asp, we were able to detect a single band at 32 kilodaltons (KD) in the serum of all patients between 4 and 36 h after infusion. The molecular weight remained unchanged and no other bands occurred during the time of observation. The detection limit of this method was calculated to 5 micrograms/ml using radial immunodiffusion. Incubation of l-Asp with pooled normal human serum caused no degradation of the enzyme during 48 h at 37 degrees C. Neither the total enzyme nor fragments were detectable in the urine of the patients collected during 8 h after l-Asp infusion. From these results we conclude that l-Asp is not cleaved by proteases in humans. The enzyme is most probably eliminated by the reticuloendothelial system.
- Published
- 1989